Table of Contents
Table of Contents
Preface
Chapter 1. Introduction: Cardiotoxicity of Chemotherapeutic Agents
Jalaj Garg MD FESC, Neeraj Shah MD MPH and Gregg M. Lanier MD (Division of Cardiology, Lehigh Valley Health Network, Allentown, USA, and others)
Chapter 2. Alkylating Agents
Jalaj Garg MD, Varun Mittal MD, Neeraj Shah MD, Abhishek Sharma, Vidhu Anand MD and Gregg M. Lanier MD (Division of Cardiology, Lehigh Valley Health Network, Allentown, USA, and others)
Chapter 3. Antimetabolites
Jalaj Garg MD FESC, Varun Mittal MD, Neeraj Shah MD MPH, Abhishek Sharma MD, Vidhu Anand MD and Gregg M. Lanier MD (Division of Cardiology, Lehigh Valley Health Network, Allentown, USA, and others)
Chapter 4. Antitumor Antibiotics: Bleomycin and Mitoxantrone
Rahul Gupta MD, Rahul Chaudhary MD, Vidhu Anand MD, Abhishek Sharma MD, Gurprataap Singh Sandhu MD and Gregg M. Lanier MD (Queens Cardiac Care, Queens, USA, and others)
Chapter 5. Antitumor Antibiotics: Anthracyclines, a Mechanism of Cardiotoxicity
Rahul Chaudhary MD, Rahul Gupta MBBS, Vidhu Anand MD, Abhishek Sharma MD, Gurprataap Singh Sandhu MD and Gregg M Lanier MD (Division of Medicine, Sinai Hospital of Baltimore, USA, and others)
Chapter 6. Antitumor Antibiotics: Anthracyclines, Cardiotoxicity and Associated Risk Factors
Rahul Chaudhary MD, Rahul Gupta MBBS, Vidhu Anand MD, Abhishek Sharma MD, Gurprataap Singh Sandhu MD and Gregg M. Lanier MD (Division of Medicine, Sinai Hospital of Baltimore, USA, and others)
Chapter 7. Antitumor Antibiotics: Anthracyclines and Minimizing Cardiotoxicity
Rahul Chaudhary MD, Rahul Gupta MBBS, Vidhu Anand MD, Abhishek Sharma MD, Gurprataap Singh Sandhu MD and Gregg M. Lanier MD (Division of Medicine, Sinai Hospital of Baltimore, USA, and others)
Chapter 8. Antitumor Antibiotics: Newer Anthracyclines
Rahul Gupta MD, Rahul Chaudhary MD, Vidhu Anand MD, Abhishek Sharma MD, Gurprataap Singh Sandhu MD and Gregg M. Lanier MD. (Queens Cardiac Care, Queens, USA, and others)
Chapter 9. Microtubule Inhibitors
Brijesh Patel DO, Rahul Gupta MBBS, Jalaj Garg MD FESC, Naveen Sablani MD MS, Ronak Patel MD FACC and Gregg M. Lanier MD (Division of Cardiology, Lehigh valley Health Network, Allentown, USA, and others)
Chapter 10. Hormonal Therapy
Jalaj Garg MD FESC, Mahek Shah MD, Rahul Chaudhary MD, Rahul Gupta MBBS, Ronak Patel MD FACC and Gregg M Lanier MD (Division of Cardiology, Lehigh Valley Health Network, Allentown, USA, and others)
Chapter 11. Immunotherapy
Nayan Agarwal MD, Rahul Gupta MBBS, Abhishek Sharma MD, Rudhir Tandon MD, Rahul Chaudhary MD, Raman Dusaj MD and Gregg M. Lanier MD (Division of Cardiology, University of Florida, Gainesville, USA, and others)
Chapter 12. Monoclonal Antibodies
Jalaj Garg MD FESC, Nayan Agarwal MD, Neeraj Shah MD MPH, Rahul Gupta MBBS, Nainesh C Patel MD FACC and Gregg M Lanier MD FACC (Division of Cardiology, Lehigh Valley Health Network, Allentown, USA, and others)
Chapter 13. Tyrosine Kinase Inhibitors
Mahek Shah MD, Rahul Gupta MBBS, Rahul Chaudhary MD, Nainesh C Patel MD FACC and Gregg M Lanier MD (Division of Cardiology, Lehigh Valley Health Network, Allentown, USA, and others)
Chapter 14. Topoisomerase-1 Inhibitors and Miscellaneous Drugs
Rahul Chaudhary MD, Nikhil Mukhi MD, Rahul Gupta MBBS, Jalaj Garg MD FESC, Philip Carson MD, Neeraj Shah MD MPH, Gregg M. Lanier MD (Division of Medicine, Sinai Hospital of Baltimore, USA, and others)
About the Editors
Index
Additional Information
We hope that our book serves as a valuable reference in the field of cardiac oncology for the clinicians who are actively involved in the management of patients receiving, antineoplastic agents, including primary care physician, cardiologist, cardiology fellows in training and oncologist.
